Placeholder

Ledipasvir

  • # LGM Pharma is a Ledipasvir CAS# 1256388-51-8 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Ledipasvir
  • CAS #: 1256388-51-8
  • Mode of Action:

    Mutations that confer resistance to Ledipasvir in Hepatitis C Virus replicon cells, which are found in NS5A, infer that NS5A is the direct target of Ledipasvir.

  • Pharmacodynamics:

    Ledipasvir is a novel Hepatitis C Virus NS5A inhibitor that is best administered adjunctively with other antiviral drugs, leading to very successful results. A cure rate of up to 100 percent is possible when Ledipasvir is used in the correct combinations of drug cocktails. By effectively inhibiting the viral phosphoprotein NS5A Ledipasvir aids in controlling viral assembly, replication and secretion.

  • Metabolism:

    Ledipasvir is primarily eliminated in the feces, with a renal excretion being considered as a minor elimination pathway. Whole blood and plasma levels of Ledipasvir are undetectable at both 36 and 48 hours post dosage.

  • Toxicity:

    Reports that Ledipasvir, when used in combination with Sofosbuvir and Tenofovir may increase Tenofovir levels in the body. While severe toxicity has not been documented a concern regarding co-administration of Tenofovir with Ledipasvir may lead to renal toxicity. The majority of adverse effects reported are not severe and include fatigue, nausea, dizziness and diarrhea.

  • PubChem: 67505836
  • Formula: C49-H54-F2-N8-O6
  • Molecular Mass: 889.0116
  • Synonyms: GS 5885, GS-5885, GS5885, Ledipasvir, UNII-013TE6E4WV, WHO 9796
  • SMILES: CC(C)[C@@H](C(=O)N1CC2(CC2)C[C@H]1c3[nH]c(cn3)c4ccc-5c(c4)C(c6c5ccc(c6)c7ccc8c(c7)[nH]c(n8)[C@@H]9[C@H]1CC[C@H](C1)N9C(=O)[C@H](C(C)C)NC(=O)OC)(F)F)NC(=O)OC
  • General Reference:
    1. PLoS One. 2015 Apr 9;10(4):e0122844. doi: 10.1371/journal.pone.0122844. eCollection 2015.
    2. Infect Drug Resist. 2014 Mar 5;7:41-56. doi: 10.2147/IDR.S36247. eCollection 2014.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants

 

  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. We’re working to update our website to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service